GlassScriptPhysician profile
Pamela Ralph
NPI 1205953858
$2,887.57
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $523 · 2021: $398 · 2022: $692.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $459.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $412.14 | 2019-2021 | |
| Allergan, INC. | $337.66 | 2019-2020 | |
| Lundbeck LLC | $262.11 | 2019-2021 | |
| Abbvie INC. | $229.62 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $214.05 | 2019-2022 | |
| Alkermes, INC. | $155.17 | 2022 | |
| Tris Pharma INC | $129.86 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $124.99 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $103.55 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.30 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $87.66 | 2019-2020 | |
| Neos Therapeutics, LP | $62.46 | 2019 | |
| Supernus Pharmaceuticals, INC. | $58.98 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $52.32 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $27.39 | 2020 | |
| Avanir Pharmaceuticals, INC. | $26.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $26.08 | 2019 | |
| Shire North American Group INC | $25.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Ralph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.